🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Publication of the SUNLIGHT clinical trial results in NEJM marks the potential importance of the trial & the impact these results may have on treatment options for people living with refractory metastatic #colorectalcancer. Read more here: bit.ly/3nAAzK6 #TaihoCares

We are onsite at #ASCO23 where scientific exchange takes center stage in the pursuit of advancing care for patients with cancer. Take a look at what some of our Taiho experts have to say about the significance of this meeting and visit us at Booth 12123. #TaihoCares

#WorldLungCancerDay is a rallying point to raise awareness of the global impact of #lungcancer. At Taiho Oncology, we are passionate about advancing patient care & have joined the lung cancer research community in working to develop potential new therapeutic options. #TaihoCares

The U.S. FDA has approved an important new treatment option for adults with metastatic #colorectalcancer (mCRC). Learn what this milestone may mean for patients living with mCRC. #TaihoCares

As we recognize #BloodCancerAwarenessMonth throughout September, we thank patient advocacy groups, including AA&MDSIF, The Leukemia & Lymphoma Society, and MDS Foundation, for providing resources and support to patients and their loved ones, this month and year-round. #TaihoCares

Today is #MDSWorldAwarenessDay and we are helping raise awareness of myelodysplastic syndromes (MDS) and patient advocacy organizations including AA&MDSIF, MDS Foundation and The Leukemia & Lymphoma Society, that are dedicated to providing support for people living with these rare diseases. #TaihoCares

Attending #ASH23? Taiho Oncology and Astex Pharmaceuticals are looking forward to helping contribute to the scientific exchange in support of advancing patient care. Please take a look at our joint press release announcing details of studies we are presenting at the meeting.

Today at #ASH23, Taiho Oncology announced results of a U.S. real-world study of an oral treatment in patients with myelodysplastic syndromes (MDS), a rare form of #bloodcancer. Learn more: taihooncology.com/us/news/2023-1… #TaihoCares

Today, we’re announcing publication of the final results of the Phase 3 ASCERTAIN clinical trial in patients with myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML). Learn more about the results: bit.ly/4b7oKiA #TaihoCares

Advancing care for patients with cancer is our top priority. In recognition of #WorldCancerDay today, Taiho Oncology’s Mike Mitchell speaks to his role in helping #CloseTheCareGap to ensure all patients have access to meaningful treatments. #TaihoCares

Taiho Oncology announced today presentations at ASH, Dec. 7-10, 2024, in San Diego. Results of Phase 1 oral azacitidine plus cedazuridine (ASTX030) combination trial in patients with myelodysplastic syndromes (#MDS) will be shared. #ASH2024 taihooncology.com/us/news/2014_1…

Taiho Oncology presented results of two studies focused on oral therapies for patients with #myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) at the 66th ASH Annual Meeting. Learn more here: taihooncology.com/us/news/taiho-… #ASH2024

Taiho announces presentations ASCO-#GI25. Real-world clinical outcomes of patients with metastatic colorectal cancer who received trifluridine and tipiracil (FTD/TPI) monotherapy or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy will be shared. bit.ly/4h0vXDT

Taiho Oncology announces oral drug combination part of next-generation trials targeting specific genetic mutations in patients with myelodysplastic syndromes and acute myeloid leukemia.​ bit.ly/42dCaYh

Taiho Oncology presents real-world data about the pairing of LONSURF® (trifluridine/tipiracil) with bevacizumab as a combination treatment at the 2025 ASCO Gastrointestinal Cancers Symposium #GI25. bit.ly/3EbcT78

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, and Cullinan Therapeutics, announced the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with non-small cell lung cancer, met its primary endpoint. Read more: bit.ly/4azfggd

Taiho Oncology will share data in five presentations, including two oral presentations, at the 2025 ASCO Annual Meeting. Details about these presentations can be found here: taihooncology.com/us/news/taiho-…

Taiho Oncology to share important data in several #cancer types at the 2025 ASCO Annual Meeting. Details about these presentations can be found here: taihooncology.com/us/news/taiho-…

Taiho Oncology, Cullinan Therapeutics, and Taiho Pharmaceutical announced the presentation of positive results from pivotal Phase 2b of the REZILIENT1 trial of zipalertinib at ASCO 2025. Learn more: taihooncology.com/us/news/cullin…

Taiho Oncology and @CullinanTX are pleased to announce Journal of Clinical Oncology has published new data on zipalertinib in EGFR exon20ins+ #NSCLC. #oncology #ASCO2025​ bit.ly/3FzWnib